Nivolumab + Ipilimumab

Treatment for Malignant skin melanoma

Typical Dosage: Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV every 3 weeks for 4 doses, then Nivolumab 240 mg IV every 2 weeks or 480 mg IV every 4 weeks

Effectiveness

93%

Safety Score

30%

Clinical Trials

Participants

5.5K

Comparative Safety Scale(Higher is safer)

Cyanide☠️

Meth💀

Cigarettes🚬

Chemo☢️

Alcohol🍺

Morphine💊

Antibiotics💉

Tylenol💊

Exercise🏃

Water💧

DangerousModerateSafe

Treatment Details

Dosage Range

Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV every 3 weeks for 4 doses, then Nivolumab 240 mg IV every 2 weeks or 480 mg IV every 4 weeks

Time to Effect

2-4 months

Treatment Duration

1-2 years

Evidence Quality

HIGH

Confidence Score

95%confidence in effectiveness data

Health Economics

Annual Cost of Care

Drug Cost:$300,000

Monitoring:$25,000

Side Effect Mgmt:$30,000

Total Annual:$355,000

Cost-Effectiveness Analysis

Cost-Effectiveness Rating

POOR

ICER

$350,000/QALY

QALYs Gained

Outcome-Based Costs

Cost per Responder

$612,069

Cost per Remission

$1,420,000

Comparison vs Nivolumab

Cost Difference

+$150,000/year

More expensive

QALY Difference

+0.50 QALYs

Better outcomes

Dominance

No dominance

Nivolumab + Ipilimumab Outcomes

for Malignant skin melanoma

Efficacy Outcomes

Overall Effectiveness

+93%

Response Rate

+58%

Remission Rate

+25%

Common Side Effects

Fatigue

+55%

Diarrhea/Colitis

+45%

Rash/Pruritus

+45%

Nausea/Vomiting

+25%

Hepatitis

+15%

Endocrinopathies

+15%

Sources:

nih.gov

researchgate.net

nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT

Active Clinical Trials

9 active trials recruiting for Nivolumab + Ipilimumab in Malignant skin melanoma

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

NCT06794775RECRUITINGPHASE3

WARNING: LIMITED TRIALS AVAILABLE

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

Melanoma Metastasized to the Brain and Steroids

Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

SUPRAME-ACTengine® IMA203 vs. Investigator&#x27;s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED

Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma

An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma